NLSP: NLS Pharmaceutics Ltd. Company Short-Term Debt

NLS Pharmaceutics AG (NLSP) maintains a strong reputation for developing safe treatments for sleep disorders, as evidenced by the asset's market value of 0.00 shown on this chart. The company focuses on correcting biorhythms to enhance brain productivity. Meanwhile, business development relies on external investments and clinical trial results, as stable operating profit has not yet been achieved.

For the biotech NLS Pharmaceutics (NLSP), whose capital is directed toward R&D without current revenue, this indicator reflects a dependence on external financing to maintain operations. By summing liabilities with a maturity of up to one year, the volume of short-term liabilities demonstrates the company's liquidity, where low values confirm financial stability and protect shares from sharp crashes.